Sucampo Pharmaceuticals — Q1 2017 Earnings Presentation
24 slides from Sucampo Pharmaceuticals's earnings presentation, May 3, 2017
Slide 1: First Quarter 2017 Corporate Update and Financial Results
First Quarter 2017 Corporate Update and Financial Results May 3, 2017 1
Slide 2: Introductions and Forward-Looking Statements
Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs
Slide 3: Agenda
Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener , D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenleaf 3
Slide 4: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to dif fer
Slide 5: Non-GAAP Metrics
Non - GAAP Metrics This presentation contains three financial metrics ( Adjusted Net Income, EBITDA , Adjusted EBITDA and Free Cash Flow ) that are considered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metrics
Slide 6: Q1 2017 Corporate Update
Q1 2017 Corporate Update Peter Greenleaf, Chairman and CEO
Slide 7: Vtesse Inc. Acquisition
Vtesse Inc. Acquisition • Sucampo acquired Vtesse, including its orphan drug candidate for Niemann - Pick Type C1 (NPC - 1), VTS - 270, for $200 million upfront consideration • VTS - 270 for the treatment of NPC - 1 in global pivotal registration program • Ultra - rare disorder with devastating and
Slide 8: Strong Q1 2017 U.S. AMITIZA Performance
Strong Q1 2017 U.S. AMITIZA Performance • Takeda’s AMITIZA net sales for royalty calculation purposes • Q1 grew 12% YoY to $102M • Driven by increased volume and price • Royalty revenue grew 12% YoY to $18M • U.S. AMITIZA product sales to Takeda of $11M • Total U.S. revenue of $30M • AMITIZA TRx • Q
Slide 9: Strong Japan AMITIZA Performance
Strong Japan AMITIZA Performance • Sucampo Q1 revenue: $20M, growth of 38% YoY • Growth driven by volume • Increased 34% YoY • Patient demand remains strong 9
Slide 10: 2017 Guidance Maintained
2017 Guidance Maintained • Total revenue: $220 million to $230 million • Adjusted net income: $56 million to $66 million • Adjusted EBITDA: $109 million to $119 million • Adjusted EPS: $1.00 to $1.10 • Free cash flow of $86 million to $96 million 10
Slide 11: Pipeline Update
Pipeline Update Peter Kiener, D. Phil, CSO 11
Slide 12: VTS-270 for Treatment of NPC-1
VTS - 270 for Treatment of NPC - 1 • VTS - 270 is a highly - purified mixture of 2 - hydroxypropyl - ß - cyclodextrins with a specific compositional fingerprint that targets cholesterol and sphingolipid storage • Early pre - clinical and clinical data have shown encouraging results • Recently, data
Slide 13: VTS-270 Pivotal Trial
VTS - 270 Pivotal Trial 13 13 Until regulatory decision • IT injections every 2 weeks • Trial fully enrolled • Pivotal data expected in mid - 2018 • Potential regulatory approval in U.S. and EU in 1H19 • Phase 1 patients currently in Part C on therapy >36 months 12 months for any single subject Part
Slide 14: Product Pipeline
Product Pipeline 14 Sucampo Program Option
Slide 15: Financial Update
Financial Update Peter Pfreundschuh , CFO 15
Slide 16: Continued Financial and Operational Performance
Continued Financial and Operational Performance Q1 REVENUE • Overall revenue grew 19% YoY to $56M • Product sales grew 28% to $34M • Product royalty revenue grew 12% to $18M EARNINGS Summary of Results Q1 - 17 % Increase / (Decrease) over Q1 - 16 Net Income GAAP $4.6M 214% EPS GAAP – diluted $0.10 2
Slide 17: Q1 Revenue
Q1 Revenue 17 [VALUE] 1.4 1.9 0.2 56.3 47.2 0.0 10.0 20.0 30.0 40.0 50.0 60.0 Q1 2016 Amitiza Japan product sales Amitiza US product sales Amitiza US royalty Other Q1 2017
Slide 18: Q1 Adjusted Net Income
Q1 Adjusted Net Income 18 13.0 8.9 7.1 3.0 0.3 11.5 6.5 3.9 0.7 9.8 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 Q1 2016 Gross margin Acquisition related exp Non-Operating expense Restructuring/ severance Inventory step-up Tax rate R&D License Option Exp Other Q1 2017
Slide 19: Key Balance Sheet Items
Key Balance Sheet Items Balance Sheet End 3/31/17 End 12/31/16 Cash, Cash Equivalents and Restricted Cash $243.7M $45.2M $198.5M Notes Payable $291.0M $0.5M $290.5M Net Debt $47.3M. ($44.7M) $92.0M $ sucampo
Slide 20: Closing Remarks
Closing Remarks Peter Greenleaf, Chairman and CEO 20
Slide 21: 2017 Areas of Focus
2017 Areas of Focus 1. Deliver outstanding financial performance 2. Progress proprietary pipeline programs 3. Evaluate and execute on additional opportunities for growth
Slide 22: Q&A Session
Q&A Session
Slide 23: Reconciliation of GAAP Net Income to Non-GAAP Net Income
Reconciliation of GAAP Net Loss to Non - GAAP Net Income RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended March 31, 2017 March 31, 2016 Adjusted Net Income: GAAP net income (loss) 4,624 (4,057) Amortization intang
Slide 24: Reconciliation of Income from Operations to Adjusted EBITDA
Reconciliation of Income from Operations to Adjusted EBITDA RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (in thousands, except per share amounts) Three Months Ended Three Months Ended March 31, 2017 March 31, 2016 GAAP net income 4,624 (4,057) Adjustments: Taxes 3,585 (3,038) Interest expens
Sucampo Pharmaceuticals — Q1 2017 Earnings Presentation on 6ix